Alivus Life Sciences Key Ratios

Stock Card

NSE: GLS | BSE: 543322

₹1,480.60

₹-16.60 (-1.11%)

As on 06-Nov-2026IST

Market cap

₹18,206 Cr

Revenue (TTM)

₹2,684 Cr

P/E Ratio

27.2

P/B Ratio

Div. Yield

0.3 %

Key Ratios and Highlights

Growth Score (%)	Quarterly		Annual (TTM)
Particulars	QoQ	YoY	1-Year	3-Years	5-Years
Revenue	6.49	15.99	8.19	4.75	5.50
EBIT	27.33	51.41	24.77	8.17	6.37
Net Profit	22.91	51.31	29.94	10.88	10.72
EPS	22.88	51.20	26.13	9.77	12.56
Book Value	--	--	18.24	15.91	31.15

Key Ratios (%)	Average		Annual (TTM)
Particulars	3-Years	5-Years	TTM	Mar-26	Mar-25
EBIT-Margin	27.18	27.31	31.31	28.29	26.06
Net Margin	20.73	20.62	24.24	21.61	20.06
Return on equity	19.50	22.14	19.79	18.41	18.94
Return on Capital	26.14	30.14	--	24.61	25.50
Return on Assets	13.86	14.71	16.78	14.27	13.34
Debt to Equity (x)	--	--	0.00	0.00	0.00

Profitability

View Detailed Peer Comparison

ROCE

Earning before interest and taxes / (Average net worth + Average total Debt) * 100

Company Name	TTM	Mar-26	Mar-25	Mar-24	Mar-23	Mar-22	Mar-21	Mar-20	Mar-19	Mar-18	Mar-17
Alivus Life Sciences	--	24.61	25.50	28.31	30.01	42.24
Peer Median	--	12.41	16.46	15.49	17.37	17.62

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

ROE

19.79

Higher than Peers by 10.53

Profit after tax / Average Net worth * 100

Company Name	TTM	Mar-26	Mar-25	Mar-24	Mar-23	Mar-22	Mar-21	Mar-20	Mar-19	Mar-18	Mar-17
Alivus Life Sciences	19.79	18.41	18.94	21.15	22.33	29.87
Peer Median	9.27	13.36	13.87	14.72	15.70	18.36

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

ROA

16.78

Higher than Peers by 9.46

Profit after tax / Average Total assets * 100

Company Name	TTM	Mar-26	Mar-25	Mar-24	Mar-23	Mar-22	Mar-21	Mar-20	Mar-19	Mar-18	Mar-17
Alivus Life Sciences	16.78	14.27	13.34	13.96	15.43	16.57
Peer Median	7.32	7.23	8.04	7.19	9.43	9.43

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

EBIT Margin

31.31

Higher than Peers by 22.03

Operating profit (EBIT) / Net Sales * 100

Company Name	TTM	Mar-26	Mar-25	Mar-24	Mar-23	Mar-22	Mar-21	Mar-20	Mar-19	Mar-18	Mar-17
Alivus Life Sciences	31.31	28.29	26.06	27.19	27.77	27.23
Peer Median	9.28	17.33	10.05	10.28	13.90	17.27

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Net Margin

24.24

Higher than Peers by 15.48

Net profit / Total Income (Net sales plus other income) * 100

Company Name	TTM	Mar-26	Mar-25	Mar-24	Mar-23	Mar-22	Mar-21	Mar-20	Mar-19	Mar-18	Mar-17
Alivus Life Sciences	24.24	21.61	20.06	20.52	21.32	19.59
Peer Median	8.76	11.16	9.11	6.78	10.91	12.99

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Cash Profit Margin

(Net profit + Depreciation) / Gross Sales * 100

Company Name	TTM	Mar-26	Mar-25	Mar-24	Mar-23	Mar-22	Mar-21	Mar-20	Mar-19	Mar-18	Mar-17
Alivus Life Sciences	--	24.81	22.79	22.90	23.43	21.48
Peer Median	--	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Growth

View Detailed Peer Comparison

Revenue Growth

8.19

Higher than Peers by 1.68

Year on year growth in net sales

Company Name	TTM	Mar-26	Mar-25	Mar-24	Mar-23	Mar-22	Mar-21	Mar-20	Mar-19	Mar-18	Mar-17
Alivus Life Sciences	8.19	6.91	4.54	5.64	1.79	12.63
Peer Median	6.51	21.12	7.17	10.56	12.63	15.47

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

EBIT Growth

24.77

Higher than Peers by 25.44

Year on year growth in operating profit (EBIT)

Company Name	TTM	Mar-26	Mar-25	Mar-24	Mar-23	Mar-22	Mar-21	Mar-20	Mar-19	Mar-18	Mar-17
Alivus Life Sciences	24.77	16.07	0.19	3.43	3.81	3.68
Peer Median	-0.67	29.02	12.05	6.17	-2.90	51.73

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Net Profit Growth

29.94

Higher than Peers by 22.36

Year on year growth in profit after tax

Company Name	TTM	Mar-26	Mar-25	Mar-24	Mar-23	Mar-22	Mar-21	Mar-20	Mar-19	Mar-18	Mar-17
Alivus Life Sciences	29.94	16.24	3.13	0.84	11.52	19.10
Peer Median	7.58	26.27	22.15	27.97	-14.10	44.15

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

EPS Growth

26.13

Higher than Peers by 25.58

Year on year growth in earnings per share

Company Name	TTM	Mar-26	Mar-25	Mar-24	Mar-23	Mar-22	Mar-21	Mar-20	Mar-19	Mar-18	Mar-17
Alivus Life Sciences	26.13	16.05	3.12	0.84	11.52	4.78
Peer Median	0.55	15.70	8.80	--	-3.68	38.52

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Book Value Growth

Year on year growth in book value per share

Company Name	TTM	Mar-26	Mar-25	Mar-24	Mar-23	Mar-22	Mar-21	Mar-20	Mar-19	Mar-18	Mar-17
Alivus Life Sciences	--	18.43	20.94	8.90	3.94	172.44
Peer Median

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Solvency

View Detailed Peer Comparison

Debt to Equity

Total debt / Net worth

Company Name	TTM	Mar-26	Mar-25	Mar-24	Mar-23	Mar-22	Mar-21	Mar-20	Mar-19	Mar-18	Mar-17
Alivus Life Sciences	--	--	--	--	--	--
Peer Median	0.02	0.17	0.03	0.05	0.14	0.23

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Short term debt to equity ratio

(Short term borrowings / Net worth)

Company Name	TTM	Mar-26	Mar-25	Mar-24	Mar-23	Mar-22	Mar-21	Mar-20	Mar-19	Mar-18	Mar-17
Alivus Life Sciences	--	--	--	--	--	--
Peer Median

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Current Ratio

5.08

Higher than Peers by 2.68

Current Assets / Current Liabilities and Provisions

Company Name	TTM	Mar-26	Mar-25	Mar-24	Mar-23	Mar-22	Mar-21	Mar-20	Mar-19	Mar-18	Mar-17
Alivus Life Sciences	5.08	4.14	4.97	4.37	2.33	2.85
Peer Median	2.40	2.09	2.20	1.93	1.82	1.75

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Quick Ratio

3.69

Higher than Peers by 1.99

(Current Assets - Inventory) / Current Liabilities and Provisions

Company Name	TTM	Mar-26	Mar-25	Mar-24	Mar-23	Mar-22	Mar-21	Mar-20	Mar-19	Mar-18	Mar-17
Alivus Life Sciences	3.69	3.12	3.53	2.85	1.74	2.16
Peer Median	1.71	1.62	1.72	1.59	1.30	1.04

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Interest Coverage

165.03

Higher than Peers by 155.04

Earning before interest and taxes (EBIT) / Interest Expenses

Company Name	TTM	Mar-26	Mar-25	Mar-24	Mar-23	Mar-22	Mar-21	Mar-20	Mar-19	Mar-18	Mar-17
Alivus Life Sciences	165.03	140.86	271.97	409.34	1,150.19	21.20
Peer Median	9.99	10.26	12.28	12.45	16.98	15.07

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Operating Efficiency

View Detailed Peer Comparison

Debtors to sales

36.81

Higher than Peers by 9.88

Debtors outstanding / Net Sales * 100

Company Name	TTM	Mar-26	Mar-25	Mar-24	Mar-23	Mar-22	Mar-21	Mar-20	Mar-19	Mar-18	Mar-17
Alivus Life Sciences	36.81	42.05	40.63	33.52	37.33	31.72
Peer Median	26.93	32.97	26.23	23.97	24.57	20.26

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Asset Turnover

0.67

Lower than Peers by 0.03

Sales / Average Total Assets

Company Name	TTM	Mar-26	Mar-25	Mar-24	Mar-23	Mar-22	Mar-21	Mar-20	Mar-19	Mar-18	Mar-17
Alivus Life Sciences	0.67	0.65	0.66	0.68	0.72	0.84
Peer Median	0.70	0.65	0.74	0.88	0.82	0.79

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Receivable days

Average Debtors / Sales * 365

Company Name	TTM	Mar-26	Mar-25	Mar-24	Mar-23	Mar-22	Mar-21	Mar-20	Mar-19	Mar-18	Mar-17
Alivus Life Sciences	--	144.58	132.12	125.30	124.34	111.01
Peer Median

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Inventory Days

Average Inventory / Sales * 365

Company Name	TTM	Mar-26	Mar-25	Mar-24	Mar-23	Mar-22	Mar-21	Mar-20	Mar-19	Mar-18	Mar-17
Alivus Life Sciences	--	96.67	102.08	101.28	94.11	88.40
Peer Median

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Payable days

Average Creditors / Cost of goods sold * 365

Company Name	TTM	Mar-26	Mar-25	Mar-24	Mar-23	Mar-22	Mar-21	Mar-20	Mar-19	Mar-18	Mar-17
Alivus Life Sciences	--	135.45	133.54	149.95	136.29	94.72
Peer Median

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Cash Conversion Cycle

Receivable Days + Inventory Days - Payable Days

Company Name	TTM	Mar-26	Mar-25	Mar-24	Mar-23	Mar-22	Mar-21	Mar-20	Mar-19	Mar-18	Mar-17
Alivus Life Sciences	--	105.80	100.66	76.63	82.16	104.69
Peer Median

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Valuation

View Detailed Peer Comparison

Price / Earnings

27.18

Lower than Peers by 11.47

Current share price divided by earning per share in the last twelve months

Company Name	TTM	Mar-26	Mar-25	Mar-24	Mar-23	Mar-22	Mar-21	Mar-20	Mar-19	Mar-18	Mar-17
Alivus Life Sciences	27.18	21.18	27.24	20.17	10.28	13.43
Peer Median	38.65	46.83	39.17	40.74	25.97	33.71

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Price / Book Value

5.01

Higher than Peers by 1.36

Current share price divided by book value per share in the latest financial year

Company Name	TTM	Mar-26	Mar-25	Mar-24	Mar-23	Mar-22	Mar-21	Mar-20	Mar-19	Mar-18	Mar-17
Alivus Life Sciences	5.01	3.60	4.71	4.09	2.25	2.74
Peer Median	3.65	4.70	3.61	3.87	2.79	4.36

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Dividend Yield

0.34

Higher than Peers by 0.23

Dividend per share in the past twelve months divided by current share price

Company Name	TTM	Mar-26	Mar-25	Mar-24	Mar-23	Mar-22	Mar-21	Mar-20	Mar-19	Mar-18	Mar-17
Alivus Life Sciences	0.34	0.51	0.46	2.90	5.36	4.58
Peer Median	0.11	0.11	0.19	0.20	0.65	0.28

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

EV/EBITDA

18.15

Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)

Company Name	TTM	Mar-26	Mar-25	Mar-24	Mar-23	Mar-22	Mar-21	Mar-20	Mar-19	Mar-18	Mar-17
Alivus Life Sciences	18.15	13.94	18.35	13.40	6.69	8.10
Peer Median	--	42.19	28.79	25.41	15.07	23.32

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Market Cap

18,206

Higher than Peers by 13,165

Current Share price multiplied by latest total number of shares outstanding

Company Name	TTM	Mar-26	Mar-25	Mar-24	Mar-23	Mar-22	Mar-21	Mar-20	Mar-19	Mar-18	Mar-17
Alivus Life Sciences	18,206	11,957	13,229	9,499	4,798	5,624
Peer Median	5,041	5,195	3,944	2,959	3,742	6,050

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly